Price is sometimes an indicator of quality, whether on equity markets or elsewhere. But just because a stock has a low sticker price doesn't mean it isn't worth considering. Investors can find highly promising corporations whose shares are changing hands for under $20 apiece.

Let's consider two examples: (NASDAQ: EXEL) and Snap (NYSE: SNAP). While these two companies have encountered issues recently, both are worth holding on to for the long haul. Here is why.

Humans have yet to eradicate diseases. Until that happens, biotech companies like Exelixis will be incredibly valuable. Moreover, this drugmaker focuses on one of the deadliest illnesses: cancer. Exelixis has created an in-house culture centered around developing oncology medicines, particularly where an unmet need exists. The company is best known for Cabometyx, which treats certain forms of liver and kidney cancer. 

Continue reading

Source Fool.com